Vivani Medical, Inc.
VANI Healthcare Biotechnology
In the quarter to June 2026, EPS grew 41.7% and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow VANI
Vivani Medical, Inc. (VANI) EV/Sales
As of 16 October 2026, Vivani Medical, Inc. (VANI) trades at a EV/Sales of 23.6×. Over the past ten years it has ranged from −5.1× (December 2022) to 141× (March 2015); the current reading is higher than 75% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2019 | 22.6× | 186.35% |
| FY2018 | 7.9× | (37.88%) |
| FY2017 | 12.7× | (24.62%) |
| FY2016 | 16.8× | (22.36%) |
| FY2015 | 21.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2019 | 22.6× | 24.04% |
| Sep 2019 | 18.2× | 62.16% |
| Jun 2019 | 11.2× | 67.09% |
| Mar 2019 | 6.7× | (14.80%) |
| 16 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MIST Milestone Pharmaceuticals Inc. compare | −2.4× |
| PYPD PolyPid Ltd. compare | n/m |
| BDTX Black Diamond Therapeutics, Inc. compare | n/m |
| UNCY Unicycive Therapeutics, Inc. compare | n/m |
| CYTT Cyteir Therapeutics, Inc. compare | n/m |
| VTVT vTv Therapeutics Inc. compare | 6.5× |
| COYA Coya Therapeutics, Inc. compare | 8.7× |
| VANI Vivani Medical, Inc. | 23.6× |
| INO Inovio Pharmaceuticals, Inc. compare | 157× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)